- Home
- ZNTL vs GECC Comparison
ZNTL vs GECC Comparison
Compare ZNTL & GECC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- GECC
- Stock Information
- Founded
- ZNTL 2014
- GECC 2016
- Country
- ZNTL United States
- GECC United States
- Employees
- ZNTL N/A
- GECC N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- GECC Finance: Consumer Services
- Sector
- ZNTL Health Care
- GECC Finance
- Exchange
- ZNTL Nasdaq
- GECC Nasdaq
- Market Cap
- ZNTL 105.8M
- GECC 122.4M
- IPO Year
- ZNTL 2020
- GECC N/A
- Fundamental
- Price
- ZNTL $1.24
- GECC $10.90
- Analyst Decision
- ZNTL Buy
- GECC
- Analyst Count
- ZNTL 7
- GECC 0
- Target Price
- ZNTL $8.60
- GECC N/A
- AVG Volume (30 Days)
- ZNTL 1.4M
- GECC 20.1K
- Earning Date
- ZNTL 08-08-2025
- GECC 07-31-2025
- Dividend Yield
- ZNTL N/A
- GECC 14.21%
- EPS Growth
- ZNTL N/A
- GECC N/A
- EPS
- ZNTL N/A
- GECC 0.42
- Revenue
- ZNTL $26,865,000.00
- GECC $42,909,000.00
- Revenue This Year
- ZNTL N/A
- GECC $32.54
- Revenue Next Year
- ZNTL N/A
- GECC N/A
- P/E Ratio
- ZNTL N/A
- GECC $25.48
- Revenue Growth
- ZNTL N/A
- GECC 18.13
- 52 Week Low
- ZNTL $1.01
- GECC $8.87
- 52 Week High
- ZNTL $5.44
- GECC $11.39
- Technical
- Relative Strength Index (RSI)
- ZNTL 39.75
- GECC 53.81
- Support Level
- ZNTL $1.31
- GECC $10.28
- Resistance Level
- ZNTL $1.39
- GECC $10.85
- Average True Range (ATR)
- ZNTL 0.11
- GECC 0.25
- MACD
- ZNTL -0.03
- GECC -0.01
- Stochastic Oscillator
- ZNTL 8.91
- GECC 51.06
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.